The acquisition of Icad Inc.’s brachytherapy business by Elekta AB takes the company a step closer to achieving its goal of providing hope to the millions of people dealing with cancer, John Lapré, president of Elekta’s Brachy and Neuro Solutions unit, told BioWorld. Elekta paid approximately $5.5 million for Icad’s subsidiary Xoft. In addition, most of Xoft’s staff and its main facility in San José, Calif., was transferred to the company.
Oncopia Therapeutics Inc. (dba Proteovant Therapeutics Inc.) and the University of Michigan have jointly patented molecular glue degraders targeting cereblon (CRBN) and acting as zinc finger protein Helios (IKZF2) degradation inducers.
Eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) degradation inducers have been reported in a Bristol Myers Squibb Co. patent as potentially useful for the treatment of cancer.
Researchers from Ambrx Inc. and Novocodex Biopharmaceuticals Co. Ltd. presented preclinical data for ARX-305, a next-generation anti-CD70 antibody-drug conjugate (ADC), being developed for the treatment of CD70-expressing cancers.
Abbisko Therapeutics Co. Ltd. has received FDA clearance of its IND application for ABSK-012, a highly selective small-molecule inhibitor of fibroblast growth factor receptor 4 (FGFR4), for advanced solid tumors.
Acetylenic lipids extracted from plants or marine sponges are known to have relevant cytotoxicity against tumoral cells. Previous work has shown that structural modifications to lipidic alkynylcarbinol (LAC) underpin specific changes in its cytotoxic activity.
Propanc Biopharma Inc. has announced that PRP enhances the sensitivity of resistant pancreatic tumor cells to standard chemotherapy treatment and alters the tumor microenvironment by decreasing the fibrotic tissue and its malignancy.
RSS
